Tobinick
Edward L. Tobinick, Santa Monica, CA US
Patent application number | Description | Published |
---|---|---|
20100150933 | CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - A method of treating a nerve disorder mediated by nucleus pulposus in a mammal in need thereof, comprising: administering to said mammal a TNF-α inhibitor that is a monoclonal antibody which blocks TNF-α activity, thereby inhibiting TNF-α and treating said disorder. | 06-17-2010 |
Edward L. Tobinick, Los Angeles, CA US
Patent application number | Description | Published |
---|---|---|
20120148583 | CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - A method for delivering a biologic pharmaceutical, comprising: administering an effective amount of a biologic pharmaceutical to a patient in need thereof by perispinal injection, without direct intrathecal or direct epidural injection. | 06-14-2012 |
Edward L. Tobinick, Boca Raton, FL US
Patent application number | Description | Published |
---|---|---|
20130115211 | CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS - A method, comprising: introducing a therapeutically effective amount of a specific TNF blocker to cerebrospinal fluid of a human in need of treatment for symptoms associated with neronal compression. | 05-09-2013 |
20150079086 | Methods for treatment of brain injury utilizing biologics - A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included. | 03-19-2015 |
Edward Lewis Tobinick, Los Angles, CA US
Patent application number | Description | Published |
---|---|---|
20100129359 | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers - A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispinal space of said human without direct intrathecal injection and positioning said human in a Trendelenburg position. | 05-27-2010 |
Edward Lewis Tobinick, Los Angeles, CA US
Patent application number | Description | Published |
---|---|---|
20090130019 | Methods of perispinal extrathecal administration of large molecules for diagnostic use in mammals - This application concerns novel methods which enable or improve the ability of molecules, particularly large molecules, to cross the blood-brain barrier, the blood-eye barrier, and/or the blood-nerve barrier and therefore be of improved diagnostic and/or therapeutic use in humans and other mammals. These methods involve perispinal administration of imaging agents without direct intrathecal injection. Perispinal administration is defined as administration of the molecule into the anatomic area within 10 cm of the spine. Perispinal administration results in absorption of the imaging agent into the vertebral venous system. The vertebral venous system is capable of transporting molecules into the brain, the eye, the retina, the auditory apparatus, the cranial nerves, the head, the spine, the spinal cord, the vertebral bodies, the dorsal root ganglia, and the nerve roots via retrograde venous flow, thereby bypassing the blood-brain barrier and similar barriers and delivering the molecules to the brain, the eye, the retina, the auditory apparatus, the cranial nerves, the head, the spine (including the vertebral bodies), the spinal cord, the dorsal root ganglia, or the nerve roots. This method may be utilized for a wide variety of diagnostic agents, including, but not limited to biologics, monoclonal antibodies, fusion proteins, monoclonal antibody fragments, antibodies to tumor antigens, hormones, cytokines, anti-cytokines, interleukins, anti-interleukins, interferons, colony-stimulating factors, cancer chemotherapeutic agents, growth factors, anti-virals and antibiotics, including those which are radiolabeled, iodinated, or otherwise altered to facilitate diagnostic imaging. Included in these novel methods are perispinal delivery of amyloid imaging agents, and other ligands radiolabeled with [11C] or [18F] to faciliate PET imaging of the brain. | 05-21-2009 |
20130022540 | METHODS TO FACILITATE TRANSMISSION OF LARGE MOLECULES ACROSS THE BLOOD-BRAIN, BLOOD-EYE, AND BLOOD-NERVE BARRIERS - A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispina! space of said human without direct intrathecal injection and positioning said human in a Trendelenburg position. | 01-24-2013 |
Edward Lewis Tobinick, Boca Raton, FL US
Patent application number | Description | Published |
---|---|---|
20130224197 | Methods for treatment of brain injury utilizing biologics - A method of using biologics to treat chronic brain injury or spasticity due to stroke, trauma and other causes. Preferred embodiments include perispinal, parenteral, transepidermal or intranasal use of TNF antagonists. The TNF antagonists include TNF receptor fusion proteins, TNF monoclonal antibodies (mAbs), humanized TNF mAbs, fully human TNF mAbs, chimeric TNF mAbs, domain TNF antibodies, mAB fragments, anti-TNF nanobodies, dominant negative TNF constructs and TNF inhibitory single chain antibody fragments. One of the preferred embodiments of this invention is the perispinal administration of etanercept for treatment of mammals following stroke. The use of Trendelenburg positioning, catheters, pumps, or depot formulations are included. | 08-29-2013 |